STVN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Stevanato Group SpA (STVN) is not a strong buy at the moment for a long-term beginner investor. While the company shows solid financial growth trends and has a stable market position, the technical indicators and lack of significant positive catalysts suggest waiting for a better entry point. The stock is currently trading in a neutral zone with no strong bullish signals.
The MACD is positive and expanding, indicating a potential bullish trend. However, the RSI is neutral at 58.686, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level (R1: 16.481), which could limit further upside in the short term.
The company has shown strong financial performance in Q3 2025, with revenue up 9.11% YoY, net income up 20.11% YoY, and EPS up 18.18% YoY. Gross margin also improved by 6.31%. Additionally, the upcoming Q4 2025 earnings release on March 4, 2026, could provide further insights into the company's performance.
Analyst sentiment is cautious, with Jefferies lowering the price target from $23 to $17.50 and maintaining a Hold rating due to headwinds in the injectable packaging market. The bearish moving averages and lack of significant insider or hedge fund activity further weaken the case for a strong buy.
In Q3 2025, the company reported revenue of $303.17M (up 9.11% YoY), net income of $36.06M (up 20.11% YoY), EPS of $0.13 (up 18.18% YoY), and gross margin of 29.82% (up 6.31% YoY). These figures indicate consistent growth and operational efficiency.
Jefferies has lowered the price target to $17.50 from $23 and maintained a Hold rating, citing headwinds in the injectable packaging market. KeyBanc remains optimistic about the injectable GLP-1 market but notes limited risk from oral weight loss drugs until 2030.
